JAMMU, Nov 9 : Union Minister
of State (Independent Charge) for Science and Technology and Earth Sciences,
Minister of State in the Prime Minister’s Office, Department of Atomic Energy,
Department of Space, and Personnel, Public Grievances and Pensions, Dr Jitendra
Singh, today reviewed the progress of the Cannabis Medicinal Research Project
at CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu, with a
particular focus on its potential medical applications.Buy Maps
Cannabis is sought to be
developed as export quality painkillers, sending out a message that a substance
infamous for drug addiction, could also bring relief to mankind, said Dr
Jitendra Singh.
Describing the initiative as
India's first-of-its-kind cannabis research project, Dr Singh said it is
expected to pave the way for the development of export-quality medicines for
neuropathies, cancer, epilepsy and Acute Respiratory Distress Syndrome (ARDS).
He said the project has been undertaken through a Public-Private Partnership
(PPP) model, with the participation of a French company, and is aimed
exclusively at exploring the medicinal and life-science applications of
cannabis. Highlighting the therapeutic potential of cannabis, particularly its
use in pain management, the Minister said appropriate regulatory provisions
have been put in place to ensure its cultivation and utilisation strictly for
scientific research and medical purposes.
Dr Jitendra Singh noted that
permission for cannabis cultivation in Jammu and Kashmir had been secured after
sustained efforts, marking an important step towards advancing scientific
research in this emerging field.
Emphasising the collaborative
framework underpinning the initiative, Dr Singh said the project reflects Prime
Minister Narendra Modi's vision of a Whole-of-Government and Whole-of-Society
approach. It brings together the Government of India, the Government of Jammu
and Kashmir and private-sector partners in a coordinated effort to harness
scientific innovation for societal benefit. He described it as a
Whole-of-Nation initiative aimed at ensuring that the benefits of scientific
research reach society at large.
The Minister said the
initiative holds considerable potential to deliver both economic and medicinal
dividends. Besides facilitating the development of promising therapeutic
products, the project is expected to strengthen India's position in global
scientific research, innovation and the development of high-quality medicines
for international markets.
Dr Jitendra Singh said the
project is now moving towards pre-clinical trials, for which engagement has
been established with Tata Memorial Centre, Mumbai, one of India's leading
institutions in cancer treatment and research. He said that following
successful completion of the pre-clinical studies and requisite regulatory
processes, the project would move towards drug production.
Earlier, presenting an
overview of the project's progress, Dr Zabeer Ahmed, Director, CSIR-IIIM and
CSIR-NBRI, Lucknow, briefed the Minister on the scientific work undertaken by
the institute and the progress made in identifying potential cannabis-based
drug candidates. He further informed that the institute had submitted an
application to the J&K Excise Department seeking permission for
GMP-compliant manufacturing and transportation of cannabis material exclusively
for scientific purposes. The permission is required to manufacture research
material for mandatory pre-clinical regulatory studies and to advance promising
drug candidates towards clinical evaluation, he added.Buy Maps
The review meeting was
attended by Commissioner Secretary, Department of Science and Technology,
Government of Jammu and Kashmir, Babila Rakwal; Commissioner, Excise, J&K,
Vaibhav Kohli; scientists and senior officers of the concerned departments and
CSIR-IIIM.
The Cannabis Research Project,
which received permission from the Jammu and Kashmir Government in 2017 for
scientific cultivation and research, is among the pioneering initiatives in the
country to examine the medicinal properties of cannabis. CSIR-IIIM has
established protected cultivation facilities and developed a repository of more
than 500 cannabis accessions to support research and identify varieties with
potential therapeutic applications.
No comments:
Post a Comment